Company Encyclopedia
View More
name
Prelude Therapeutics
PRLD.US
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
1.946 T
PRLD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking136/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-103.99%E
    • Profit Margin-1064.50%E
    • Gross Margin100.00%A
  • Growth ScoreB
    • Revenue YoY250.00%A
    • Net Profit YoY15.01%C
    • Total Assets YoY-51.95%E
    • Net Assets YoY-62.58%E
  • Cash ScoreB
    • Cash Flow Margin-9.39%D
    • OCF YoY250.00%A
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreB
    • Gearing Ratio38.23%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges

    Prelude Therapeutics' Q3 earnings call highlighted strategic advancements, a strong financial partnership with Incyte, and plans to advance two development candidates into clinical trials by 2026. The company faces challenges in differentiating its products in competitive markets and ensuring timely clinical progress. The Incyte collaboration could bring up to $910 million, supporting long-term growth. However, competition and clinical development timelines present hurdles. Investors will watch how Prelude navigates these challenges.

    Tip Ranks·
    US
    PRLD
    +11.59%
    Tip Ranks·
    US
    PRLD
    +11.59%

    Prelude Therapeutics (NASDAQ:PRLD) Issues Earnings Results

    Prelude Therapeutics reported quarterly earnings of ($0.26) per share, beating the consensus estimate of ($0.41). The stock rose 2.6% to $1.39. Analysts have mixed ratings, with a consensus "Hold" and a target price of $4.00. Institutional investors own 79.72% of the stock. The company is developing several cancer treatments in clinical trials.

    Market Beat·
    US
    PRLD
    +11.59%
    Market Beat·
    US
    PRLD
    +11.59%

    Prelude Therapeutics Advances Pipeline and Strengthens Financials

    Prelude Therapeutics, Inc. (PRLD) reported its Q3 earnings, highlighting advancements in its oncology pipeline, including JAK2V617F and KAT6A programs expected to enter clinical development by 2026. The company achieved a reduced net loss of $19.7 million, with decreased R&D and administrative expenses. Strategic collaborations, including a $60 million payment from Incyte, strengthened its financial position. Prelude is advancing its degrader antibody conjugates and exploring new therapeutic targets, maintaining a focus on clinical program advancement and financial stability through 2027.

    Tip Ranks·
    US
    PRLD
    +11.59%
    Tip Ranks·
    US
    PRLD
    +11.59%

    Prelude Therapeutics Reports Q3 2025 Financial Results

    Prelude Therapeutics reported its Q3 2025 financial results, showing a reduced net loss of $19.7 million and a cash runway projected into 2027. The company is advancing its JAK2V617F inhibitor and KAT6A degrader programs, with IND filings expected in 2026. Analyst ratings for PRLD stock indicate a Buy with a $5.00 price target, though concerns remain due to ongoing losses and a negative P/E ratio. The company focuses on precision oncology, targeting specific mutations in cancer cells.

    Tip Ranks·
    US
    PRLD
    +11.59%
    Tip Ranks·
    US
    PRLD
    +11.59%

    Prelude Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 6.5 M

    LB filings·
    US
    PRLD
    +11.59%
    LB filings·
    US
    PRLD
    +11.59%
    © 2025 Longbridge｜Disclaimer